搜索
Uniqure NV
QURE添加自选
47.390USD
+1.330+2.89%
交易中 （美东）报价延迟15分钟
2.99B总市值
亏损市盈率 TTM
关键数据
46.010今开
47.470最高
265.58K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.42%换手率
46.060昨收
46.000最低
8.97M成交额
亏损市盈率静
20.00市净率
0.00%股息率 TTM
-30.18%ROA
71.50052周最高
0.46量比
-239.56M净利润
63.03M总股本
-3.4918每股收益TTM
0.72Beta
-228.24%ROE
7.76052周最低
3.19%振幅
93.85%毛利率
2.99B总市值
10.09回报/风险
6.27%风险率
TradingKey Uniqure NV股票评分
单位: USD 更新时间: 2026-06-30操作建议
Uniqure NV当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名73/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价64.83。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Uniqure NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Uniqure NV亮点
亮点风险
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
业绩增长期
公司处于发展阶段，最新年度总收入16.10M美元
估值低估
公司最新PE估值-13.19，处于3年历史低位
机构加仓
最新机构持股65.80M股，环比增加2.38%
李·安斯利持仓
明星投资者李·安斯利持仓，最新持仓市值453.32K
活跃度增加
近期活跃度增加，过去20天平均换手率0.35
分析师目标
根据
15
位分析师
买入
评级
64.833
目标均价
+36.81%
涨幅空间
Uniqure NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Uniqure NV简介
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
公司代码QURE
公司Uniqure NV
CEOKapusta (Matthew)
网址https://www.uniqure.com/
相关品种
热门品种
常见问题
Uniqure NV(QURE)的当前股价是多少？
Uniqure NV(QURE)的当前股价是 46.06。
Uniqure NV的股票代码是什么？
Uniqure NV的股票代码是QURE。
Uniqure NV股票的52周最高点是多少？
Uniqure NV股票的52周最高点是71.50。
Uniqure NV股票的52周最低点是多少？
Uniqure NV股票的52周最低点是7.76。
Uniqure NV的市值是多少？
Uniqure NV的市值是3.13B。
现在Uniqure NV(QURE)的股票是买入、持有还是卖出？
根据分析师评级，Uniqure NV(QURE)的总体评级为买入，目标价格为64.83。
Uniqure NV(QURE)股票的每股收益（EPS TTM）是多少
Uniqure NV(QURE)股票的每股收益（EPS TTM）是-3.46。